Carrara

Researchers are conducting a large prospective, observational cohort study to assess the clinical impact of new monoclonal antibodies (MAB) in treating B-cell Non-Hodgkin Lymphoma (NHL) within Italian clinical practice. The study focuses on patients needing treatment for B-cell NHL, including those receiving first-line or relapsed/refractory therapy. The novel MAB being studied have received approval from the European Medicines Agency (EMA) since 2020 and are prescribed according to authorized marketing indications in Italy. Participants will receive novel MAB treatments either alone or in combination, prescribed based on EMA-approved indications since 2020. Patients will be grouped into cohorts according to the treatment indication, antibody type, and lymphoma subtype, with additional sub-cohorts created if necessary. This design allows analysis by indication, antibody type, subtype, and overall evaluation of the entire patient cohort. Throughout the study, researchers will collect clinical information to evaluate the use, feasibility, efficacy, and toxicity of these novel antibodies. Key outcomes measured over at least five years include overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and incidence of early and late adverse events. Participants will be closely monitored for both short- and long-term effects of the treatments.

Researchers are evaluating the use of Computed Tomography Coronary Angiography (CTCA) to better understand coronary artery disease (CAD) in patients who are suspected of having this condition. The goal is to pool a large group of patients who have undergone CTCA to assess how well this test helps in identifying the presence and severity of CAD and predicting future heart-related events. This study focuses on determining the reliability of CTCA in defining disease burden and cardiovascular risk, considering major adverse cardiovascular events (MACE) such as cardiac death, unstable angina, and heart attacks as primary outcomes. The study collects retrospective data from patients who underwent CTCA using 16-slice or higher CT technology, with a minimum follow-up period of 12 months (or over 4 years for 16-slice CT). Patients included have suspected CAD and also had their coronary calcium score measured. The CTCA involves detailed imaging with contrast material and may include medications like beta-blockers or nitroglycerine to improve image quality. Researchers classify patients based on the presence and severity of coronary plaques seen on CTCA, distinguishing between normal arteries, non-obstructive disease, and obstructive disease. Participants' data, including cardiovascular risk factors and symptoms, are gathered from clinical records, interviews, and follow-up visits or phone contacts. Researchers monitor clinical events such as cardiac death, heart attacks, unstable angina, and revascularization procedures for at least 6 months. The study analyzes the relationship between CTCA findings and patient outcomes using statistical methods to identify predictors of risk and the added value of CTCA beyond traditional calcium scoring. The study aims to include over 1000 patients for robust analysis.